Exploring IB6 as a Therapeutic Target in Non–Small Cell Lung Cancer - Episode 6

Unmet Needs to Address in Advanced NSCLC

,

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.

EP. 1: Treatment Approaches and Unmet Needs in Second-Line Advanced NSCLC
EP. 2: Rationale for Evaluating IB6 as a Potential Therapeutic Target in NSCLC
EP. 3: Evaluation of Sigvotatug Vedotin Monotherapy in Previously Treated, Nonsquamous NSCLC
EP. 4: Exploring Sigvotatug Vedotin–Based Combinations in Advanced NSCLC
EP. 5: Novel Biomarkers to Watch in Advanced NSCLC
Now Viewing
EP. 6: Unmet Needs to Address in Advanced NSCLC

Related Content:

Exploring IB6 as a Therapeutic Target in Non–Small Cell Lung CancerOncLive News Network®Lung Cancer
VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors
Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC